Feb 2021 Schuller Saturday, 02/06/21 04:46:10 PM Re: None 0 Post # of 98248 Several months before Regens program was halted they put together a clean company directly owned by Regen called KCL therapeutics. The purpose was for an easy quick sale of any one of their programs through a clean company. All officers and board member shares are restricted and some were transferred to KCL.
There was some collaboration with several US companies including Pfizer and Novartis and I believe Takeda in Japan. Also a French company I don't remember. They were trying do develop too much in house and ran out of funds.
Since the Covid era began I assume the RNA program would get some attention. RNA has become a cash cow for the bigger pharma with everyone else playing catch up. For companies with little or no program Regen could be an instant boost.
Point being maybe Regen is not starting up but someone has come knocking. As of Friday the companies is valued approx $5 million dollars. Their RNA program with patents and dosage/efficacy tests done to date are worth many many time their value. Their Hema program is FDA approved to begin Phase 1 testing.
They were also showing great results in IBS testing.
The NR2F6 was their flagship program with a large number of patents associated with that Checkpoint Inhibitor.
DcellVac was something they believed would bigger but never started.
The reason that only the CFO is the sole officer is to keep all patents and licenses up to date. Whether now or down the road they know how valuable their assets are.
If there is any contact happening, someone always knows. I have seen zero pump. No articles, bots, social media nothing. Lot of volume and walked down with a few million shares everyday. The only reason we're now posting are the few who noticed that volume. Some entity is accumulating it seems.
Personally have never sold a share and and picked up more lately. To much potential value here. Hope this is informative.
Market Data 
Markets 
AI
